These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 7577460

  • 41. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
    Su J, Gu Y, Pruijn FB, Smaill JB, Patterson AV, Guise CP, Wilson WR.
    J Biol Chem; 2013 Dec 27; 288(52):37138-53. PubMed ID: 24196959
    [Abstract] [Full Text] [Related]

  • 42. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M.
    J Med Chem; 1995 May 12; 38(10):1786-92. PubMed ID: 7752202
    [Abstract] [Full Text] [Related]

  • 43. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
    Lartigau E, Stern S, Guichard M.
    Cancer Radiother; 2000 May 12; 4(3):217-22. PubMed ID: 10897765
    [Abstract] [Full Text] [Related]

  • 44. One-electron reductive bioactivation of 2,3,5,6-tetramethylbenzoquinone by cytochrome P450.
    Goeptar AR, te Koppele JM, van Maanen JM, Zoetemelk CE, Vermeulen NP.
    Biochem Pharmacol; 1992 Jan 22; 43(2):343-52. PubMed ID: 1310854
    [Abstract] [Full Text] [Related]

  • 45. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554).
    Aboagye EO, Lewis AD, Tracy M, Workman P.
    Biochem Pharmacol; 1997 Dec 01; 54(11):1217-24. PubMed ID: 9416972
    [Abstract] [Full Text] [Related]

  • 46. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M, Stevens G.
    Melanoma Res; 1998 Dec 01; 8(6):510-5. PubMed ID: 9918413
    [Abstract] [Full Text] [Related]

  • 47. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, Wilson WR.
    Biochem Pharmacol; 2012 Mar 01; 83(5):574-85. PubMed ID: 22182429
    [Abstract] [Full Text] [Related]

  • 48. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins.
    Walton MI, Wolf CR, Workman P.
    Int J Radiat Oncol Biol Phys; 1989 Apr 01; 16(4):983-6. PubMed ID: 2703406
    [Abstract] [Full Text] [Related]

  • 49. Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
    Hunter FW, Young RJ, Shalev Z, Vellanki RN, Wang J, Gu Y, Joshi N, Sreebhavan S, Weinreb I, Goldstein DP, Moffat J, Ketela T, Brown KR, Koritzinsky M, Solomon B, Rischin D, Wilson WR, Wouters BG.
    Cancer Res; 2015 Oct 01; 75(19):4211-23. PubMed ID: 26297733
    [Abstract] [Full Text] [Related]

  • 50. Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia.
    Melo T, Ballinger JR, Rauth AM.
    Biochem Pharmacol; 2000 Sep 01; 60(5):625-34. PubMed ID: 10927020
    [Abstract] [Full Text] [Related]

  • 51. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV.
    Biochem Pharmacol; 2007 Sep 15; 74(6):810-20. PubMed ID: 17645874
    [Abstract] [Full Text] [Related]

  • 52. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ, Moini M, Giuliano J, Westra WH.
    Ann Acad Med Singap; 1996 May 15; 25(3):397-404. PubMed ID: 8876907
    [Abstract] [Full Text] [Related]

  • 53. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun 15; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 54. Genotoxic effects of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and nitrogen mustard-N-oxide (nitromin) in Walker carcinoma cells under aerobic and hypoxic conditions.
    Cahill A, Jenkins TC, Pickering P, White IN.
    Chem Biol Interact; 1995 Mar 30; 95(1-2):97-107. PubMed ID: 7697757
    [Abstract] [Full Text] [Related]

  • 55. Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation.
    Robin H, Senan S, Workman P, Graham MA.
    Cancer Chemother Pharmacol; 1995 Mar 30; 36(3):266-70. PubMed ID: 7781150
    [Abstract] [Full Text] [Related]

  • 56. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW, Jaiswal JK, Hurley DG, Liyanage HD, McManaway SP, Gu Y, Richter S, Wang J, Tercel M, Print CG, Wilson WR, Pruijn FB.
    Biochem Pharmacol; 2014 May 15; 89(2):224-35. PubMed ID: 24632291
    [Abstract] [Full Text] [Related]

  • 57. Acute lesions in rats caused by 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) or nitromin: a comparison with rates of reduction in microsomal systems from target organs.
    White IN, Cahill A, Davies A, Carthew P.
    Arch Toxicol; 1992 May 15; 66(2):100-6. PubMed ID: 1605723
    [Abstract] [Full Text] [Related]

  • 58. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
    Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, Stratford IJ.
    Cancer Res; 2004 Feb 15; 64(4):1396-402. PubMed ID: 14973055
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation.
    Govaert KM, Nijkamp MW, Emmink BL, Steller EJ, Minchinton AI, Kranenburg O, Borel Rinkes IH.
    Br J Surg; 2012 Apr 15; 99(4):567-75. PubMed ID: 22331808
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.